Intratumoral Cancer Therapies Global Market Report 2024

Description

“Intratumoral Cancer Therapies Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on intratumoral cancer therapies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for intratumoral cancer therapies? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The intratumoral cancer therapies market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

1) By Technology: Monoclonal Antibodies; Vaccines; Checkpoint Inhibitors; Cell Therapies; Immunes System Modulator; Adoptive Cell Transfer; Cytokines
2) By Application: Lung Cancer; Breast Cancer; Malenoma; Prostate Cancer; Head and Neck Cancer; Other Applications
3) By End Users: Hospitals; Cancer Research Centers; Clinics
Companies Mentioned: Amgen Inc.; AstraZeneca plc; Bayer AG; Bristol-Myers Squibb Company; Pfizer Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Intratumoral cancer therapies involve treatments directly administered or applied to a tumor. These therapies are specifically crafted to target tumor cells and can be employed in conjunction with other cancer treatments, such as chemotherapy and radiation therapy.

The primary categories of intratumoral cancer therapies encompass monoclonal antibodies, vaccines, checkpoint inhibitors, cell therapies, immune system modulators, adoptive cell transfer, and cytokines. Monoclonal antibodies denote a specific type of artificially created protein capable of binding to particular bodily targets, including antigens present on the surface of cancer cells. They find application in various contexts, such as lung cancer, breast cancer, melanoma, prostate cancer, head and neck cancer, among others, and are utilized by diverse end users, including hospitals, cancer research centers, and clinics.

The intratumoral cancer therapies market research report is one of a series of new reports from The Business Research Company that provides intratumoral cancer therapies market statistics, including intratumoral cancer therapies industry global market size, regional shares, competitors with an intratumoral cancer therapies market share, detailed intratumoral cancer therapies market segments, market trends and opportunities, and any further data you may need to thrive in the intratumoral cancer therapies industry. This intratumoral cancer therapies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The intratumoral cancer therapies market size has grown rapidly in recent years. It will grow from $124.82 billion in 2023 to $141.55 billion in 2024 at a compound annual growth rate (CAGR) of 13.4%. The growth observed in the historical period can be ascribed to advancements in cancer research, a rise in cancer incidence, the demand for precision medicine, clinical evidence and research initiatives, as well as unmet medical needs.

The intratumoral cancer therapies market size is expected to see rapid growth in the next few years. It will grow to $221.46 billion in 2028 at a compound annual growth rate (CAGR) of 11.8%. The anticipated growth in the forecast period can be attributed to advancements in immunotherapy, a heightened adoption of precision medicine, the expansion of clinical trials, a growing focus on rare cancers, and regulatory support with subsequent approvals. Major trends expected in the forecast period include the exploration of intratumoral immunomodulators, the integration of image-guided therapies, the application of hyperthermia in intratumoral treatments, the initiation of clinical trials for combination therapies, and continued regulatory backing for intratumoral therapies.

The rising prevalence of cancer is anticipated to drive the expansion of the intratumoral cancer therapies market in the foreseeable future. Cancer comprises a group of diseases characterized by the uncontrolled proliferation and dissemination of abnormal cells within the body. Intratumoral cancer therapies play a crucial role in the diagnosis and treatment of cancer by mitigating off-target toxicities, dose-limiting toxicities, and adverse effects resulting from immune stimulation in patients with cancer. For instance, as of January 2023, the American Cancer Society, a nonprofit cancer advocacy organization based in the United States, reported an increase in the number of cancer cases to 1,958,310, representing a growth of 3.16% from 1,898,160 in 2021. This, escalation in cancer incidence is a significant factor propelling the growth of the intratumoral cancer therapies market.

The integration of immunotherapy is expected to fuel the growth of the intratumoral cancer therapies market. Immunotherapy, a cancer treatment that enhances the body's immune system to identify and destroy cancer cells, is becoming increasingly prominent. Intratumoral therapies align with the growing emphasis on immunotherapy, providing a targeted and potent approach to modulating the immune response within the tumor microenvironment. Notably, in June 2022, the United States Food and Drug Administration (FDA) approved 35 ICI-based combination immunotherapies, highlighting the increasing integration of immunotherapy and its impact on the intratumoral cancer therapies market.

Technological advancements emerge as a noteworthy trend in the intratumoral cancer therapies market. Companies in this sector are adopting innovative technologies to maintain their market standing. For instance, in March 2022, Evonik, a US-based specialty chemical manufacturing company, introduced EUDRATEC SoluFlow, a novel microparticle technology designed to enhance the solubility of active medicinal components in oral cancer medication formulations. This breakthrough technology allows previously considered insoluble chemicals to be used in a broader range of oral medications.

In September 2022, CytoReason Ltd, an Israel-based biotechnology company, partnered with Pfizer Inc. to leverage artificial intelligence (AI) for drug discovery and development. Through this collaboration, Pfizer will incorporate CytoReason's AI technologies into its drug research activities, with the agreement valued up to $110 million over the next five years. Pfizer's contribution includes $20 million in stock, options to license CytoReason's platform and disease models, and additional project support. Pfizer Inc., a US-based pharmaceutical company specializing in intestine cancer therapeutics, aims to enhance its drug discovery efforts through this collaboration.

In January 2023, AstraZeneca, a UK-based biopharmaceutical firm focusing on oncology and rare diseases, acquired Neogene Therapeutics Inc. for $120 million. This acquisition expands AstraZeneca's capabilities in cancer treatment by incorporating Neogene Therapeutics Inc., an Amsterdam-based biotechnology research company offering personalized treatments based on TCR genes targeting neoantigens detected in a specific patient's tumor.

Major companies operating in the intratumoral cancer therapies market report are Amgen Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Pfizer Inc., Novartis AG, Johnson & Johnson, Eli Lilly and Company, F. Hoffmann-la Roche, Celgene Corporation, Takeda Pharmaceutical Company Ltd., GSK plc, Ziopharm Oncology Inc., Celldex Therapeutics Inc., Astellas Pharma Inc., Sirnaomics, Checkmate Pharmaceuticals Inc., Immunovative Therapies Ltd., Idera Pharmaceuticals Inc., Daiichi Sankyo, Philogen S.p.A., Apexigen Inc., Merck Group, OncoSec Medical Incorporated, DNAtrix, Istari Oncology Inc., Nanobiotix, Exicure Inc., Karyopharm Therapeutics Inc., Dechra Pharmaceuticals PLC, Torigen Pharmaceuticals Inc., Elekta, Virbac, Norbrook Laboratories, Aratana Therapeutics Inc., Regeneus Ltd., QBiotics Group, VetDC, AdvaVet Inc

North America was the largest region in the intratumoral cancer therapies market in 2023. The regions covered in the intratumoral cancer therapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the intratumoral cancer therapies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The intratumoral cancer therapies market consists of revenues earned by entities by chemotherapy, radiation therapy, immunotherapy, and targeted therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Product Code: r11078

1. Executive Summary

2. Intratumoral Cancer Therapies Market Characteristics

3. Intratumoral Cancer Therapies Market Trends And Strategies

4. Intratumoral Cancer Therapies Market - Macro Economic Scenario

4.1. Impact Of High Inflation On the Market
4.2. Ukraine-Russia War Impact On the Market
4.3. COVID-19 Impact On the Market

5. Global Intratumoral Cancer Therapies Market Size and Growth

5.1. Global Intratumoral Cancer Therapies Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Intratumoral Cancer Therapies Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Intratumoral Cancer Therapies Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Intratumoral Cancer Therapies Market Segmentation

6.1. Global Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Monoclonal Antibodies
Vaccines
Checkpoint Inhibitors
Cell Therapies
Immunes System Modulator
Adoptive Cell Transfer
Cytokines
6.2. Global Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Lung Cancer
Breast Cancer
Malenoma
Prostate Cancer
Head and Neck Cancer
Other Applications
6.3. Global Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospitals
Cancer Research Centres
Clinics

7. Intratumoral Cancer Therapies Market Regional And Country Analysis

7.1. Global Intratumoral Cancer Therapies Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Intratumoral Cancer Therapies Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Intratumoral Cancer Therapies Market

8.1. Asia-Pacific Intratumoral Cancer Therapies Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Intratumoral Cancer Therapies Market

9.1. China Intratumoral Cancer Therapies Market Overview
9.2. China Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Intratumoral Cancer Therapies Market

10.1. India Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Intratumoral Cancer Therapies Market

11.1. Japan Intratumoral Cancer Therapies Market Overview
11.2. Japan Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Intratumoral Cancer Therapies Market

12.1. Australia Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Intratumoral Cancer Therapies Market

13.1. Indonesia Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Intratumoral Cancer Therapies Market

14.1. South Korea Intratumoral Cancer Therapies Market Overview
14.2. South Korea Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Intratumoral Cancer Therapies Market

15.1. Western Europe Intratumoral Cancer Therapies Market Overview
15.2. Western Europe Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Intratumoral Cancer Therapies Market

16.1. UK Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Intratumoral Cancer Therapies Market

17.1. Germany Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Intratumoral Cancer Therapies Market

18.1. France Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Intratumoral Cancer Therapies Market

19.1. Italy Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Intratumoral Cancer Therapies Market

20.1. Spain Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Intratumoral Cancer Therapies Market

21.1. Eastern Europe Intratumoral Cancer Therapies Market Overview
21.2. Eastern Europe Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Intratumoral Cancer Therapies Market

22.1. Russia Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Intratumoral Cancer Therapies Market

23.1. North America Intratumoral Cancer Therapies Market Overview
23.2. North America Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Intratumoral Cancer Therapies Market

24.1. USA Intratumoral Cancer Therapies Market Overview
24.2. USA Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Intratumoral Cancer Therapies Market

25.1. Canada Intratumoral Cancer Therapies Market Overview
25.2. Canada Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Intratumoral Cancer Therapies Market

26.1. South America Intratumoral Cancer Therapies Market Overview
26.2. South America Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Intratumoral Cancer Therapies Market

27.1. Brazil Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Intratumoral Cancer Therapies Market

28.1. Middle East Intratumoral Cancer Therapies Market Overview
28.2. Middle East Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Intratumoral Cancer Therapies Market

29.1. Africa Intratumoral Cancer Therapies Market Overview
29.2. Africa Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Intratumoral Cancer Therapies Market Competitive Landscape And Company Profiles

30.1. Intratumoral Cancer Therapies Market Competitive Landscape
30.2. Intratumoral Cancer Therapies Market Company Profiles
- 30.2.1. Amgen Inc.
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. AstraZeneca plc
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. Bayer AG
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. Bristol-Myers Squibb Company
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. Pfizer Inc.
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Global Intratumoral Cancer Therapies Market Competitive Benchmarking

32. Global Intratumoral Cancer Therapies Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Intratumoral Cancer Therapies Market

34. Intratumoral Cancer Therapies Market Future Outlook and Potential Analysis

34.1 Intratumoral Cancer Therapies Market In 2028 - Countries Offering Most New Opportunities
34.2 Intratumoral Cancer Therapies Market In 2028 - Segments Offering Most New Opportunities
34.3 Intratumoral Cancer Therapies Market In 2028 - Growth Strategies
- 34.3.1 Market Trend Based Strategies
- 34.3.2 Competitor Strategies

35. Appendix

35.1. Abbreviations
35.2. Currencies
35.3. Historic And Forecast Inflation Rates
35.4. Research Inquiries
35.5. The Business Research Company
35.6. Copyright And Disclaimer